ATOSSA THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-34.8M | $-25.5M | $-30.1M | $-27.0M | $-20.6M | $-17.8M | $-17.2M | $-11.4M |
| Depreciation & Amortization | — | — | — | $8.0K | $23.0K | $47.0K | $52.8K | $44.2K |
| Depreciation | $16.0K | $17.0K | $23.0K | $8.0K | $10.0K | $19.0K | $22.0K | $14.0K |
| Amortization | — | — | — | — | — | $27.6K | $30.8K | $30.0K |
| Stock-Based Compensation | $2.6M | $2.3M | $4.6M | $6.8M | — | — | — | — |
| Net Cash from Operating Activities | $-29.8M | $-21.0M | $-20.9M | $-20.8M | $-16.5M | $-11.6M | $-9.1M | $-9.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $23.0K | $19.0K | $14.0K | $27.0K | $9.0K | $9.0K | $7.6K | $110.9K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-23.0K | $-19.0K | $-14.0K | $-4.7M | $-9.0K | $-9.0K | $-7.6K | $-110.9K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $0 | $1.5M | $0 | — | — | — | — |
| Net Cash from Financing Activities | $0 | $3.7M | $-1.5M | $0 | $113.3M | $38.6M | $11.3M | $12.3M |
| Net Change in Cash | $-29.8M | $-17.4M | $-22.4M | $-25.5M | $96.8M | $27.0M | $2.2M | $3.2M |
| Free Cash Flow | $-29.8M | $-21.0M | $-21.0M | $-20.8M | $-16.5M | $-11.6M | $-9.1M | $-9.1M |